Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 91,679,488
  • Shares Outstanding, K 1,647,430
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.17
  • Price/Sales 4.70
  • Price/Cash Flow 18.05
  • Price/Book 6.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.22 +2.64%
on 07/13/17
57.90 -3.89%
on 06/22/17
-0.42 (-0.75%)
since 06/21/17
3-Month
51.56 +7.93%
on 06/07/17
57.90 -3.89%
on 06/22/17
+2.17 (+4.06%)
since 04/21/17
52-Week
46.01 +20.95%
on 01/26/17
76.80 -27.54%
on 07/27/16
-19.85 (-26.29%)
since 07/21/16

Most Recent Stories

More News
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.

MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
GILD : 73.76 (+0.46%)
BMY : 55.65 (+0.38%)
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

AZN : 34.05 (+0.47%)
JNJ : 135.31 (-0.92%)
MRK : 62.63 (-0.49%)
LLY : 84.66 (-0.11%)
NVS : 84.99 (-0.50%)
SNY : 47.71 (-0.73%)
BMY : 55.65 (+0.38%)
After Yesterday's Rally of 1.16% Shares Could Potentially Pullback

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $55.18 to a high of $55.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

BMY : 55.65 (+0.38%)
Look for Shares of Bristol-Myer Sqb to Potentially Pullback after Yesterday's 1.16% Rise

Bristol-Myer Sqb (NYSE:BMY) traded in a range yesterday that spanned from a low of $55.18 to a high of $55.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

BMY : 55.65 (+0.38%)
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

JNJ : 135.31 (-0.92%)
ABBV : 74.63 (+0.84%)
GILD : 73.76 (+0.46%)
BMY : 55.65 (+0.38%)
"Families Like Yours" Documentary Celebrates LGBT Families At World Premiere

The National Gay & Lesbian Chamber of Commerce (NGLCC), the business voice of the LGBT community, is proud to announce the world premiere of Families Like Yours, a powerful documentary exploring the love,...

DB : 18.22 (-1.30%)
BMY : 55.65 (+0.38%)
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized...

EXEL : 27.23 (+0.89%)
RHHBY : 32.2700 (+0.22%)
PFE : 33.48 (-0.18%)
BMY : 55.65 (+0.38%)
Bristol-Myer Sqb (BMY) Approaches New Downside Target of $53.99

Bristol-Myer Sqb (NYSE:BMY) has opened bearishly below the pivot of $55.38 today and has reached the first level of support at $54.51. Should the shares continue to fall, the support pivots of $53.99...

BMY : 55.65 (+0.38%)
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx

Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.

EXEL : 27.23 (+0.89%)
RHHBY : 32.2700 (+0.22%)
PFE : 33.48 (-0.18%)
BMY : 55.65 (+0.38%)
Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

MRK : 62.63 (-0.49%)
NVS : 84.99 (-0.50%)
ABBV : 74.63 (+0.84%)
BMY : 55.65 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 55.99
1st Resistance Point 55.82
Last Price 55.65
1st Support Level 55.43
2nd Support Level 55.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.